ArticleThe Korean journal of internal medicine2025
Real-world treatment outcomes in South Korean patients with epidermal growth factor receptor-mutant non-small cell lung cancer.
Article in The Korean journal of internal medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
BACKGROUND/
aimsThis study aimed to assess the real-world treatment outcomes in South Korean patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) receiving first-line (1L) EGFR tyrosine kinase inhibitors (TKIs).
methodsWe used the Health Insurance Review and Assessment Service database, which includes the data of a large proportion of the Korean population. Patients with EGFR-positive NSCLC who received gefitinib, erlotinib, or afatinib as the 1L treatment between 2012 and 2018 were included. Survival outcomes, subsequent therapies, and treatment patterns were analyzed.
resultsAmong the 9,478 patients included, gefitinib (56.68%) was the most commonly prescribed 1L EGFR-TKI, followed by afatinib (25.30%) and erlotinib (18.02%). The median time to next treatment was 16.4 to 18.8 months. Overall survival (OS) was significantly different among the three treatment groups; the median OS was 28.8, 25.3, and 23.9 months for patients who were treated with afatinib, gefitinib, and erlotinib, respectively (p < 0.001). For the patients who received second-line (2L) therapy (n = 4,904, 51.74%), pemetrexed monotherapy was most commonly used (47.70%), followed by osimertinib (21.59%). Patients who received osimertinib as the 2L treatment had longer OS compared to those receiving pemetrexed (median OS: not reached vs. 25.3 to 28.8 months).
conclusionOur real-world study demonstrated survival outcomes that were comparable to those observed in clinical trials for patients with EGFR-mutant NSCLC treated with EGFR-TKIs. Detection of the acquired T790M mutation and subsequent osimertinib treatment had significant prognostic value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.